Cardiff Oncology(DE:XE7C)
€0.66-0.04 (-1.93%)
DE:XE7C
Cardiff Oncology financials statements
€0.66
At close:-0.04 (-1.93%)
Cardiff Oncology (XE7C) Ratios
3 Followers
Cardiff Oncology Ratios
DE:XE7C's free cash flow for Q2 2026 was $-11.81M. For the 2026 fiscal year, DE:XE7C's free cash flow was decreased by $-44.00K and operating cash flow was $-11.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 |
| Quick Ratio | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 |
| Cash Ratio | 1.07 | 3.83 | 2.07 | 2.09 | 1.82 |
| Solvency Ratio | -2.72 | -3.16 | -3.45 | -3.91 | -3.05 |
| Operating Cash Flow Ratio | -2.31 | -2.81 | -2.96 | -4.33 | -3.51 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 43.63M | $ 80.81M | $ 65.51M | $ 101.44M | $ 137.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.03 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.36 | 1.17 | 1.17 | 1.09 | 1.06 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.03 | 0.05 | 0.06 | 0.08 |
| Net Debt to EBITDA | 0.37 | 1.11 | 0.43 | 0.34 | 0.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -7732.04% | -6651.68% | -9305.74% | -10337.31% | -8037.60% |
| EBITDA Margin | -7579.60% | -6592.53% | -9224.18% | -10276.17% | -7911.98% |
| Operating Profit Margin | -8256.32% | -7123.13% | -9305.74% | -10337.31% | -8037.60% |
| Pretax Profit Margin | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.50% |
| Net Profit Margin | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.50% |
| Continuous Operations Profit Margin | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.50% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 93.65% | 93.38% | 91.26% | 97.00% | 98.05% |
| Return on Assets (ROA) | -74.09% | -46.74% | -50.76% | -33.31% | -18.92% |
| Return on Equity (ROE) | -101.02% | -54.77% | -59.42% | -36.40% | -20.15% |
| Return on Capital Employed (ROCE) | -107.63% | -58.08% | -63.78% | -36.82% | -20.18% |
| Return on Invested Capital (ROIC) | -105.93% | -57.59% | -63.17% | -36.59% | -20.10% |
| Return on Tangible Assets | -74.09% | -46.74% | -50.76% | -33.31% | -18.92% |
| Earnings Yield | -24.41% | -21.97% | -62.67% | -63.41% | -12.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.26 | 0.88 | 1.69 | 0.50 | 0.67 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.49 | 0.33 | 0.17 | 0.11 | 0.11 |
| Asset Turnover | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | 112.02 | 413.10 | 215.41 | 729.05 | 543.94 |
| Days of Sales Outstanding | 112.02 | 413.10 | 215.41 | 729.05 | 543.94 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 112.02 | 413.10 | 215.41 | 729.05 | 543.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.57 | -0.79 | -0.69 | -0.78 | -0.59 |
| Free Cash Flow Per Share | -0.57 | -0.79 | -0.70 | -0.80 | -0.60 |
| Dividend Paid and CapEx Coverage Ratio | -861.89 | -471.16 | -53.07 | -25.90 | -100.61 |
| Capital Expenditure Coverage Ratio | -861.89 | -471.16 | -53.07 | -37.91 | -112.39 |
| Operating Cash Flow Coverage Ratio | -45.58 | -24.75 | -14.37 | -12.46 | -7.39 |
| Operating Cash Flow to Sales Ratio | -63.95 | -55.19 | -63.29 | -87.62 | -64.18 |
| Free Cash Flow Yield | -20.21% | -18.27% | -47.59% | -56.87% | -9.91% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.07 | -4.55 | -1.60 | -1.58 | -8.29 |
| Price-to-Sales (P/S) Ratio | 316.73 | 302.78 | 135.50 | 158.13 | 653.40 |
| Price-to-Book (P/B) Ratio | 4.14 | 2.49 | 0.95 | 0.57 | 1.67 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.95 | -5.47 | -2.10 | -1.76 | -10.09 |
| Price-to-Operating Cash Flow Ratio | -4.95 | -5.49 | -2.14 | -1.80 | -10.18 |
| Price-to-Earnings Growth (PEG) Ratio | 0.15 | -2.12 | -0.36 | -0.07 | 0.26 |
| Enterprise Value Multiple | -3.81 | -3.48 | -1.04 | -1.20 | -7.95 |
| Enterprise Value | 171.19M | 156.85M | 46.62M | 47.41M | 225.75M |
| EV to EBITDA | -3.81 | -3.48 | -1.04 | -1.20 | -7.95 |
| EV to Sales | 288.68 | 229.65 | 95.52 | 122.82 | 628.82 |
| EV to Free Cash Flow | -4.51 | -4.15 | -1.48 | -1.37 | -9.71 |
| EV to Operating Cash Flow | -4.51 | -4.16 | -1.51 | -1.40 | -9.80 |
| Tangible Book Value Per Share | 0.68 | 1.74 | 1.56 | 2.44 | 3.60 |
| Shareholders’ Equity Per Share | 0.68 | 1.74 | 1.56 | 2.44 | 3.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net Income Per Share | -0.69 | -0.95 | -0.93 | -0.89 | -0.72 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.91 | 0.97 | 0.98 |
| Research & Development to Revenue | 59.58 | 53.96 | 67.33 | 70.23 | 48.40 |
| SG&A to Revenue | 23.99 | 18.28 | 26.73 | 34.15 | 32.97 |
| Stock-Based Compensation to Revenue | 9.60 | 6.97 | 9.24 | 11.03 | 9.01 |
| Income Quality | 0.83 | 0.83 | 0.75 | 0.87 | 0.81 |
Currency in USD
